Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.70 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.59 |
| ▸ | F3 | P13726 | 3/20 | 0.59 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.59 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.59 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.59 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.59 |
| ▸ | PTPRC | P08575 | 2/20 | 0.59 |
| ▸ | PTPRF | P10586 | 2/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | ACP1 | P24666 | 2/20 | 0.59 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.59 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.59 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.59 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.59 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.59 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337079 | 0.87 | PTPN1 (0.59) | PTPN1POLBPTPN2AKR1B10PTPN6 | |
| Taraxerol SCHEMBL21264264 | 0.82 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 | |
| Taraxerol SCHEMBL15491002 | 0.82 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 | |
| Taraxerol SCHEMBL14047708 | 0.82 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 | |
| Taraxerol SCHEMBL569464 | 0.82 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 | |
| Taraxerol SCHEMBL569463 | 0.82 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 | |
| Taraxerol SCHEMBL15491005 | 0.82 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 | |
| SCHEMBL4202103 | 0.79 | PTPN1 (0.71) | PTPN1PTPN2AKR1B10PTPN6USP2 | |
| SCHEMBL29364134 | 0.76 | POLB (0.69) | PTPN1POLBPTPN2AKR1B10GPBAR1 | |
| Oleanolic_Acid SCHEMBL24916648 | 0.74 | PTPN1 (1.00) | PTPN1POLBPTPN2F3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-10722530-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10725042-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CASE WESTERN RESERVE (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| EP-2173333-B1 | COMBINATIONS OF ANTIFOLATE AGENT AND METHOXYAMINE IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017176756-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-9498489-B2 | Antimetabolite agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| CN-104958299-A | Antifolate agent combinations in the treatment of cancer | TRACON PHARMACEUTICALS INC | 2015-10-07 | — | — | CN | disclosed |
| WO-2008083107-A2 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON (US) | 2008-07-10 | — | — | WO | disclosed |
| US-7344868-B2 | Method for synthesizing ceramide-type compounds | LASSALLE LAURENT | 2008-03-18 | — | — | US | disclosed |
| US-7262032-B2 | Allele-specific mutation detection assay using an enzyme-disabling agent | AHMADIAN AFSHIN | 2007-08-28 | — | — | US | disclosed |
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| US-20060121583-A1 | New method for synthesizing ceramide-type compounds | LASSALLE LAURENT | 2006-06-08 | — | — | US | disclosed |
| US-20060088872-A1 | Allele-specific mutation detection assay | AHMADIAN AFSHIN | 2006-04-27 | — | — | US | disclosed |
| EP-1620568-A1 | ALLELE-SPECIFIC MUTATION DETECTION ASSAY | Ahmadian, Afshin (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094666-A1 | ALLELE-SPECIFIC MUTATION DETECTION ASSAY | DZIEGLEWSKA, HANNA (GB) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003070234-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | UNG, TOP2A, OGG1 | PTPN1 3141/4885POLB 32/4885PTPN2 2819/4885 |
| US-10722530-B2 | Methods of diagnosing and treating cancer | UNG, TP53, OGG1 | PTPN1 3464/4885POLB 34/4885PTPN2 3325/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | PTPN1 3464/4885POLB 34/4885PTPN2 3325/4885 |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PARP2, PARP1, PPP2CA | PTPN1 1936/4885POLB 64/4885PTPN2 1855/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | PTPN1 3455/4885POLB 24/4885PTPN2 3393/4885 |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | UNG, OGG1, MPG | PTPN1 3952/4885POLB 15/4885PTPN2 3786/4885 |
| US-10725042-B2 | Methods of diagnosing and treating cancer | UNG, NTPCR, GUSB | PTPN1 4278/4885POLB 225/4885PTPN2 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.